You asked “where’s your math” and then somehow produced a reply with zero math in it. Not even a crude expected-value calculation. Just variables floating in space. So let me show you what the actual math looks like and why your argument falls apart the moment numbers enter the room.

You brought up time preference. Fine. The real comparison isn’t “200 years vs 5 years” because nobody is modeling revenue over two centuries. The real comparison is that chronic therapies have stable, recurring revenue over a long period while a cure gives you one spike and then destroys your own future customer base. If a chronic therapy earns $6,000 a year per patient for, say, 30 years, that’s $180,000 of lifetime revenue per patient before discounting. A realistic cure might command around $60,000 once. Even before discounting, the chronic model is triple the revenue. When you discount future cashflows, chronic still wins because its revenue stream is stable, protected, and repeatable. That’s the math. No handwaving required.

Expected market returns don’t mysteriously rescue cures. They’re already baked into NPV calculations. Chronic therapies have lower revenue volatility, lower development risk, more predictable reimbursement, and better protection from substitutes. The discount rate is effectively lower because the cashflow is more reliable. That’s why any competent finance team values the chronic model more highly. This isn’t a subjective opinion. It’s just how discounted cashflow works.

Your “price premium” angle also collapses once you actually compare markets rather than per-unit price. Yes, a cure could theoretically be priced higher than a monthly pill. But cures annihilate their own future market. Chronic therapies don’t. Charging $100k once is meaningless if the market you just wiped out used to pay $6k per year for decades. Chronic revenue behaves like a long linear stream. Cure revenue behaves like a front-loaded exponential decay curve. That decay is unavoidable because your successful product eliminates the future need for itself.

Your competition scenario reverses reality. If a competitor can release a cure six months after you, then your own cure had no durable pricing power anyway. Fast follow-on competition obliterates high cure pricing immediately. A cure without monopoly protection has an NPV close to zero because payers always push prices toward marginal cost. Chronic therapies are exactly the type of product where competitive moat, reimbursement stickiness, and prescriber habits create long defensible streams of cash. Again, this is not “subjective.” It’s what actually happens.

And none of this even touches the development side. Investors don’t compare “cure vs cure.” They compare “cure vs chronic,” holding the development cost and probability of failure constant. The expected value formula is simple: EV = p · NPV(revenue) – cost. Since the NPV of chronic therapy revenue is larger in almost every major disease category, the expected value is larger too. This is why cures are pursued only in categories where chronic therapy isn’t viable or the patient population is too small to sustain lifetime sales anyway.

So no, the entire debate isn’t “subjective” and it doesn’t hinge on the mood of a hypothetical pharma executive. It’s math. People call cures a bad business model because superior business models exist and capital flows toward the model with the higher expected return. Chronic care has a structurally higher expected return because the revenue is larger, lasts longer, and is harder to compete away. You can argue about the ethics if you want. But the financial comparison isn’t ambiguous.

You asked for math. Here it is.